PIB TrackerA DNA vaccine, haemophilia gene therapy and a new antibiotic
Speaking as a physician at a Chennai convocation, the science minister named India's indigenous biomedical pipeline and argued that AI-guided, gene-driven precision medicine is the environment the next generation of doctors will practise in.
What happened
- Dr Jitendra Singh, a professor of medicine and diabetes, told the 42nd convocation of SRIHER, Chennai that the world is entering an era of AI-guided, gene-driven precision medicine, with India among the front-line providers of advanced healthcare solutions.
- He traced the shift from communicable diseases to lifestyle disorders - diabetes and cardiovascular disease - appearing at younger ages, noting that diabetes at thirty means decades of consequences and making prevention central.
- The indigenous pipeline he named: the DNA vaccine against COVID-19, continuing vaccine work on dengue and malaria, gene therapy for haemophilia, and the antibiotic nafithromycin for community-acquired bacterial pneumonia.
- Also cited: nuclear medicine research on acute lymphoblastic leukaemia and fatty liver disease, with an invitation to the institution to engage with national initiatives in genomics, biomanufacturing and nuclear medicine.
- On genomics he said integrating genomic information with clinical outcomes would allow treatment tailored to a patient's genetic profile, lifestyle and environment, while doctors must use the technology without surrendering clinical judgement.
For Prelims
- Precision medicine tailors prevention and treatment to individual variation in genes, environment and lifestyle. Its enabling technologies are next-generation sequencing, pharmacogenomics (how gene variants change drug response) and biomarker-guided therapy.
- India's genomics programmes: GenomeIndia, which sequenced 10,000 whole genomes across population groups, and IndiGen under CSIR - the reference datasets that make pharmacogenomics possible for Indian populations rather than European ones.
- DNA vaccines use a plasmid carrying the antigen gene, which host cells then express; ZyCoV-D was the world's first approved DNA vaccine for COVID-19 and was administered needle-free by jet injector. Compare mRNA vaccines, which deliver the message rather than the gene.
- Gene therapy for haemophilia targets the clotting-factor gene - Haemophilia A is a Factor VIII deficiency and Haemophilia B a Factor IX deficiency, both X-linked recessive, which is why the disease overwhelmingly affects males.
- Nafithromycin is a lactone-class ketolide developed in India against drug-resistant community-acquired bacterial pneumonia - significant because almost no new antibiotics reach the market, and antimicrobial resistance is a declared global health priority.
- Nuclear medicine uses radioisotopes for diagnosis and therapy - technetium-99m for imaging, iodine-131 for thyroid, lutetium-177 for neuroendocrine and prostate tumours; India's supply runs through BARC and BRIT, which is why the atomic energy ministry appears in a health discussion.
- The double burden of disease is the standing framework: communicable diseases persist while non-communicable diseases - cardiovascular, diabetes, cancer, chronic respiratory - now account for the majority of deaths in India, addressed through the NP-NCD programme and population-based screening under Ayushman Bharat.
- Biomanufacturing is the subject of the BioE3 policy (2024) - biotechnology for economy, environment and employment - which funds bio-foundries and biomanufacturing hubs, the industrial end of the pipeline named here.
For UPSC: A single release that names India's indigenous biomedical achievements in a citable list, with the clinical argument for prevention attached. Deploy it on health research and the double burden of disease, on AI in healthcare, and on genomics and biotechnology policy.
What it is NOT: No stage, outlay or timeline for anything named - the haemophilia gene therapy, the dengue and malaria vaccine work and the nuclear medicine research are mentioned without trial phase, sponsor or expected approval. No data on India's diabetes or cardiovascular burden despite the argument resting on it, nothing on the cost of precision therapies or who would pay for them, and nothing on genomic data protection, consent or the regulatory framework for gene therapy - which is where precision medicine actually stalls.
For Mains
Syllabus: GS3.13 · GS2.13 · Linkage L2
Anchor
The Minister for Science and Technology, speaking as a physician at a Chennai medical convocation, said the world is entering an era of AI-guided, gene-driven precision medicine, and named India's indigenous pipeline: a DNA vaccine against COVID-19, gene therapy for haemophilia, the antibiotic nafithromycin, and nuclear medicine research on leukaemia and fatty liver disease.
Substantiation (data)
He traced the epidemiological shift from communicable disease to lifestyle disorders now appearing at younger ages, arguing that diabetes diagnosed at thirty commits a patient to decades of complication management, and that prevention and early intervention are therefore central. On research he pointed to continuing vaccine work on dengue and malaria and invited the institution into national programmes in genomics, biomanufacturing and nuclear medicine.
Position
The list is better than the slogan. A DNA vaccine, a new-class antibiotic and a gene therapy for a single-gene disorder are three different kinds of capability - platform, small molecule and advanced therapy - and having all three domestically is the real claim to being a front-line provider. The clinical framing is also right: in a country where non-communicable disease arrives a decade earlier than in richer ones, prevention is the only affordable version of precision medicine.
Counterpoint
Precision medicine is expensive and India's problem is coverage. Gene therapies cost more than a lifetime of conventional treatment, genomic tailoring requires reference data for Indian populations that is only now being assembled, and none of it reaches a district hospital. There is also no mention of consent, genomic privacy or a regulatory pathway for advanced therapies - the three things that decide whether this scales or stays in teaching hospitals.
Way forward
Fund the unglamorous half: screening and early management of diabetes and hypertension at primary level, where decades of complications are actually prevented. Alongside, publish a regulatory pathway and pricing framework for advanced therapies, expand population genomic reference data, and treat nafithromycin's stewardship as seriously as its discovery.
Conclusion
The pipeline is real and worth naming. The test is whether gene-driven medicine reaches the patient who develops diabetes at thirty, or only the one who can reach a tertiary centre.
Deploys into: Health research and precision medicine · Double burden of disease and NCDs · AI in clinical practice · Genomics and biomanufacturing policy
Ministry of Science & Technology · 2026-10-22 · PRID 2326639 · PIB source ↗